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The expression of the elongated fibrinogen  chain, termed
, derives from alternative splicing of mRNA and causes an
insertion sequence of 20 amino acids. This insertion domain
interacts with the anion-binding exosite (ABE)-II of thrombin.
This study investigated whether and how  chain binding to
ABE-II affects thrombin interaction with its platelet receptors,
i.e. glycoprotein Ib (GpIb), protease-activated receptor
(PAR) 1, and PAR4. Both synthetic  peptide and fibrinogen
fragment D*, containing the elongated  chain, inhibited
thrombin-induced platelet aggregation up to 70%,with IC50 val-
ues of 42  3.5 and 0.47  0.03 M, respectively. Solid-phase
binding and spectrofluorimetric assays showed that both frag-
ment D* and the synthetic peptide specifically bind to throm-
bin ABE-II and competitively inhibit the thrombin binding to
GpIbwith ameanKi≈ 0.5 and ≈35M, respectively. Both these
 chain-containing ligands allosterically inhibited thrombin
cleavage of a synthetic PAR1 peptide, of native PAR1molecules
on intact platelets, and of the synthetic chromogenic peptide
D-Phe-pipecolyl-Arg-p-nitroanilide. PAR4 cleavage was unaf-
fected. In summary, fibrinogen  chain binds with high affinity
to thrombin and inhibits with combinedmechanisms the plate-
let response to thrombin. Thus, its variations in vivomay affect
the hemostatic balance in arterial circulation.
Fibrinogen is a key molecule in both primary and secondary
hemostasis, because of its role in forming the platelet plug by
connecting activated platelets and in forming plasma fibrin clot
upon thrombin cleavage. Fibrinogen consists of two symmetric
half-molecules, each containing a set of three different
polypeptide chains termed A, B, and . The latter contains
several sites that interact with different ligands such as other
fibrin(ogen) molecules, coagulation enzymes, growth factors,
and integrins (1). The product of thrombin digestion of fibrin-
ogen, i.e. fibrin, binds with a considerable specificity thrombin,
so that in the early studies fibrin was termed antithrombin I (2).
Thrombin has a divalent interactionwith two classes of binding
sites on fibrin, one of low affinity in the E domain and the other
of high affinity in the D domain of fibrin(ogen) molecules (3).
Binding of thrombin to fibrinogen involves sequences of both
A and B chain, which contain recognition sites in the fibrin-
ogen E domain. These recognition sites are still able to interact
with thrombin after cleavage of fibrinopeptide A and B and
form the low affinity binding site for the enzyme. The D
domains contain a  chain variant, termed , arising from an
alternative mRNA splicing (4), resulting in an elongated chain
composed of 427 instead of 411 residues. The inserted region at
the C terminus is composed of 20 amino acids (408VRPEH-
PAETEYDSLYPEDDL427), rich of acidic side chains and two
sulfate anions linked to Tyr418 and Tyr422 (5). The elongated 
chain, termed , mainly heterodimerizes in the fibrinogen
molecule with the more abundant A chain, thus generating
the A/ dimers (6). This fibrinogen, also called A/ fibrin-
ogen, shows a high inter-individual variability in the ratio to the
total fibrinogen  chain (7). The different expression of  chain
has been variably associated with thrombotic disorders both in
venous and arterial circulation.
Previous genetic studies showed, for instance, that the fibrin-
ogen -H2 haplotype is characterized by a reduced fibrinogen
 levels and reduced fibrinogen  to total fibrinogen ratio.
This haplotype is associated with a significantly increased risk
for venous thrombosis (6). Biochemical studies showed that 
chains bind to -thrombin with high affinity (8) and that the
408–427 region of  chain binds to the anion-binding exosite
(ABE)2-II of thrombin (1, 9). Moreover, fibrinopeptide B cleav-
age by thrombin from/A fibrinogen is slower than inA/A
fibrinogen (10). This effect was also associated with a reduced
lateral aggregation of fibrin fibrils. All these findings may con-
tribute to explain the reported enhanced risk for venous throm-
boembolism associated with a reduced expression of  chain.
However, at variance with these findings, other studies showed
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that fibrin fibers containing  chains are more resistant than 
chains to proteolysis by fibrinolytic enzymes (11), so that fibrin
clots containing amore abundant amount of  chains could be
associated with higher thrombotic risk. Notwithstanding the
decreased sensitivity to fibrinolytic enzymes, the influence of a
reduced expression of /A on enhanced risk for venous
thromboembolism was prevalently demonstrated in clinical
studies, although the detailed mechanism was only partially
unraveled.
At variance with venous thromboembolism, the significance
of altered expression of  chain on arterial thrombosis remains
largely elusive (6, 7, 12, 13). Platelets are major players of arte-
rial thrombus formation, as also demonstrated by the clinical
efficacy of anti-platelet agents in cardiovascular prevention.
The fibrinogen  chain, through its ability to bind to thrombin,
might enhance the amount of clot-bound thrombin, known to
be active in the presence of the heparin-antithrombin complex,
and thus scarcely inactivated by traditional anticoagulants
(heparins, indirect Factor Xa inhibitors) (3). Thus, clot-bound,
active thrombin may represent a storage pool of the enzyme,
facilitating arterial thrombus formation and growth.
In this study, we investigated the effect of the fibrinogen 
and also of its 20-amino acid-insertion peptide on the thrombin
interaction with the platelet receptors glycoprotein (Gp) Ib
and protease-activated receptors 1 and 4 (PAR1 and PAR4),
responsible for the thrombin-induced platelet activation. Frag-
ment D was used as the best surrogate to selectively study the
high affinity binding site for thrombin in  chain in a confor-
mation similar to that present in the native fibrinogenmolecule
and suitable for thrombin binding studies. This experimental
approach was aimed at assessing whether  chain can affect
platelet activation by inhibiting competitively the interaction
between the enzyme and GpIb and by acting as an allosteric
effector on PAR hydrolysis by thrombin. The obtained results
may shed light on the possible role of fibrinogen  chain on the
thrombin-induced platelet activation and thus on possible
implications on both anti-thrombotic and pro-thrombotic
properties of fibrinogen in arterial circulation, where platelets
play a central role in thrombo-hemorrhagic syndromes.
MATERIALS ANDMETHODS
Synthesis of Fibrinogen  Peptide—The fibrinogen  408–
427 peptide (408VRPEHPAETEYDSLYPEDDL427) and its
scrambled sequence peptide (PTAHDYVDEERPYLPEELSD)
as a control were synthesized by the peptide synthesis facility of
the Brain ResearchCenter at theUniversity of BritishColumbia
(Vancouver, Canada). The tyrosine residues 418 and 422 were
phosphorylated, as these residues were sulfated in natural 
chains (5). The RP-HPLC analysis showed that these peptides
were 95% pure, with a molecular mass of 2580.3  0.2 atomic
mass units, as determined by mass spectrometry.
Purification of Fibrinogen A/A and A/ D Fragments—
Both A/A (D) and A/ (D*) fragments of fibrinogen were
purified by a modified procedure, as reported previously (14).
Human fibrinogen, free of plasminogen was purchased from
Calbiochem. This preparation was chromatographed on a
DEAE-Sepharose fast flow XK column connected to a fast pro-
tein liquid chromatography apparatus (GE Healthcare) to sep-
arate the fibrinogen fraction rich in  chains. The column was
equilibratedwith 5mMsodiumphosphate, 40mMTris, pH8.50,
at a flow rate of 1ml/min.One gramof fibrinogenwas adsorbed
on the column. After the elimination of nonadsorbed proteins,
fibrinogen fractions were eluted using a stepwise gradient and
three different eluting buffer solutions as follows: 1) 30 mM
sodium phosphate, 60 mM Tris, pH 7.60; 2) 50 mM sodium
phosphate, 80 mM Tris, pH 6.80; 3) 500 mM sodium phosphate,
0.5 M Tris, pH 4.40. All these buffers contained 1 mg/ml apro-
tinin as protease inhibitor. Three major peaks were obtained,
and the fibrinogen fraction containing one A and one  chain
was eluted with the third buffer solution, whereas the fraction
containing two A chains was obtained with the first buffer. D
fragments were prepared from plasmin digests of the first and
the third peak obtained by DEAE chromatography and gel-fil-
tered on DG-10 columns (Bio-Rad) equilibrated with 50 mM
Tris-HCl, 0.15 M NaCl, 10 mM CaCl2, pH 8.50. Human plasmin
(specific activity, 5 units/mg; Calbiochem) was added at a final
concentration of 0.05 unit/ml (0.01 mg/mg fibrinogen) and
incubated with the pooled and concentrated fibrinogen peaks 1
and 3 of the DEAE chromatography in the above buffer at 25 °C
for 120 min. The fibrinogen was pretreated for 15 min with 5
mM iodoacetamide to inhibit any minimal trace of contaminat-
ing Factor XIII before the addition of plasmin. The reactionwas
stopped by the addition of aprotinin (10 mg/ml final concen-
tration). Fragment D (containing A chains only) and D* (con-
taining  chain only) were purified from peaks 1 and 3, respec-
tively, using a second DEAE column (Supelco, Sigma), 4.6 25
mm, and a two-pump HPLC apparatus (Jasco Easton, MD),
equippedwith a spectrophotometric device (model 2075), and a
spectrofluorometric detector (FP-2020, Jasco). The spectro-
photometric detection of the eluted peaks was accomplished at
280 nm, whereas the fluorescence of the proteins was moni-
tored by using ex 280 nm and em 340 nm. The developed
gradient was 0–0.5 M NaCl in 20 mM Tris-HCl, pH 8.0, in 60
min. The flow rate was 1 ml/min. Fragment D was eluted at
about 0.2 M NaCl, whereas fragment D* was obtained at0.45
M NaCl. The concentration of fragment D and D* was calcu-
lated spectrophotometrically at 280 nm using an extinction
coefficient of E0.1%  2.0 cm2mg1, using the primary
sequence of fragmentD and the spectrophotometricmethod by
Pace et al. (15). The fractions containing the fragment D andD*
were pooled and concentrated, and their purity was checked by
SDS-PAGE using 4–12% gradient gels under both not reducing
and reducing conditions. The identity of the  chain was
checked by immunoblotting of the bands obtained in SDS-
PAGE of reduced fragment D*, using a mouse anti-human
monoclonal antibody (clone 2.G2.H9) from Millipore S.p.A.
(Milano, Italy), a secondary anti-mouse horseradish peroxi-
dase-conjugated antibody, and an ECLTM Western blotting
detection system (GE Healthcare). The A chains obtained
from reduced fragment D did not react with the monoclonal
antibody 2.G2.H9 (data not shown).
Thrombin-Fragment D* Interaction—Human -thrombin
was purified and characterized as reported previously (16).
Binding of thrombin to purified fibrinogen fragment D* was
studied by a solid-phase binding assay, immobilizing fragment
D* (5 g/ml) on microtiter plates (96-well; Nunc-Immuno
Fibrinogen Chain and Thrombin-Platelet Interaction
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MaxisorpNunc), overnight at 4 °C in 50mMbicarbonate buffer,
pH 9.60. The plate surface was blocked at 37 °C for 4 h with 250
l/well of a buffer solution containing 1 mg/ml bovine serum
albumin, 50mMTris-HCl, pH 7.5. After aspiration of the block-
ing solution, plates were dried at room temperature and stored
over desiccant at 4 °C. Use of the anti  chain monoclonal
antibody 2.G2.H9 conjugated to Alexa Fluor 488 (Invitrogen)
allowed us to obtain a quantitative estimate of the amount of
immobilized fragment D*. Under the above conditions, the
amount of immobilized fragment D* was equal to about 10
ng/well (about 0.12 pmol/well). This estimate was based on the
use of serial dilutions of a reference solution of the 2.G2.H9
monoclonal antibody, whoseAlexa 488 fluorescencewasmeas-
ured using ex 494 nmandem 520 nm.Thus, atmaximum
saturation using 100 l of the buffer solution, about 1 nM
thrombin could be boundby immobilized fragmentD*. Control
experiments were also performed using fragment D instead of
fragment D* at the same concentration.
Thrombin (78 nM to 5 M) was incubated for 30 min in the
absence and presence of the C-terminal domain 45–57 of
hemadin, a specific ligand for ABE-II of thrombin (17). The
C-terminal peptide of hemadin had the sequence NH2-
SEFEEFEIDEEEK-OH and was synthesized by the solid-phase
Fmoc (N-(9-fluorenyl)methoxycarbonyl) method (18) on a
p-alkoxybenzyl ester polystyrene resin, using amethod detailed
previously (19) The chemical identity of the purified material
was established by high resolution mass spectrometry in posi-
tive ion mode on a Mariner electrospray ionization-time-of-
flight instrument from PerSeptive Biosystems (Foster City,
CA), which gave mass values in agreement with the expected
amino acid composition within 10 ppm mass accuracy. The
concentration of the peptide was determined byUV absorption
at 257 nm on either a double-beam l-2 (PerkinElmer Life Sci-
ences) or a Varian Cary 2200 spectrophotometer (Assoc. Inc.,
Sunnyvale, CA), using a molar absorption coefficient of 400
M1cm1. The hemadin peptide was used at a fixed concentra-
tion spanning from 2 to 16 M. The binding buffer was 10 mM
Tris-HCl, 0.15 M NaCl, 0.1% PEG 6000, pH 7.50, at 25 °C
(TBSP). In a different experimental setup, the C-terminal
hemadin peptide was substituted by the  peptide, used over a
22.5–180 M concentration range, to test whether or not the
latter behaves as a pure competitive inhibitor. After incubation
at 25 °C for 30 min, and aspiration with three washing cycles
with TBSP, a sheep anti-thrombin polyclonal antibody (10
mg/ml, from US Biological, Milan, Italy) was added at an opti-
mal dilution of 1:500 in TBSP and incubated for 120 min. After
aspiration of the solutions and three washing cycles, 100 l of
rabbit anti-sheep horseradish peroxidase-conjugated poly-
clonal antibody (2 mg/ml, dilution 1:250) from US Biological
(Milan, Italy) was added and incubated for 60 min at 25 °C.
After aspiration and three washing cycles, 100 l of 5 mM
3,5,3,5-tetramethylbenzidine in the presence of 5 mM H2O2
was added, and the reaction was stopped after 15min using 1 M
H2SO4. This end point was chosen based on preliminary exper-
iments showing a linear increase of the absorbance (15 points,
R 0.95) over that time interval even at the highest concentra-
tion of thrombin. This finding ruled out that the absorbance
measured after 15 min of incubation did not reflect the real
amount of thrombin bound to fragment D* and was not
because of substrate depletion. An entire data set of throm-
bin binding to fragment D* (35 points) was simultaneously
fitted to the Equation 1,
A  AmaxT/T Kd*		 (Eq. 1)
where A is the value of the absorbance measured at 450 nm;
Amax is the asymptotic value of the absorbance; T is the throm-
bin concentration; and Kd* is the apparent equilibrium dissoci-
ation constant of thrombin binding to fragmentD*, equal toKd0
(I/Ki), withKd0 as the real equilibrium binding constant; I is the
concentration of either fragment D* or  peptide, and Ki is the
equilibrium dissociation constant of binding of these ligands to
thrombin.
Binding of Fibrinogen  Peptide to Thrombin Studied by
Tryptophan Fluorescence—Binding of  peptide to thrombin
was studied by recording the increase in tryptophan fluores-
cence of thrombin at max (i.e. 334 nm) as a function of fibrin-
ogenpeptide. The interaction of the latterwith thrombinwas
monitored by adding, under gentle magnetic stirring, to a solu-
tion of thrombin (1.4 ml, 50 nM) in 5 mM Tris-HCl buffer, pH
7.5, 0.1% PEG, in the presence of 0.15 M NaCl, aliquots (2–5 l)
of  peptide (2.33mM). Fluorescence spectra were recorded on
a Jasco (Tokyo, Japan) model FP-6500 spectrofluorometer,
equipped with a Peltier model ETC-273T temperature control
system from Jasco. Excitation and emission wavelengths were
295 and 334 nm, respectively, using an excitation/emission slit
of 10 nm. For all measurements, the long time measurement
software (Jasco) was used. Control experiments were also per-
formed to ruled out not specific effects, using the  peptide
scrambled peptide at a concentration of 100 M. Under these
conditions, at the end of the titration, a Trp photobleaching
lower than 2% was observed. The absorbance of the solution at
both 295 and 334 nm was always lower than 0.05 unit, and
therefore no inner filter effect occurred during titration exper-
iments. Fluorescence intensities were corrected for dilution
(2–3% at the end of the titration) and subtracted for the contri-
bution of the ligand at the indicated concentration. The fluo-
rescence values, measured in duplicate, were analyzed as a
function of the  peptide concentration by a hyperbole equa-
tion to obtain the value of the Fmax (corresponding to the fluo-
rescence at  peptide concentration∞). This parameter was
used to calculate 
Fmax  Fmax  Fo (where Fo is the fluores-
cence value in the absence of the peptide). The fluorescence
changes expressed as (Fobs  Fo)/
Fmax were analyzed as a
function of the total  peptide concentration according to a
single site binding isotherm. Nonlinear least squares fitting was
performed using the programOrigin 7.5 (MicroCal Inc.), which
allowed us to obtain the best fitting parameter values alongwith
their standard errors.
Effect of  Peptide and Fragment D* on Thrombin-GpIb
Interaction—Solid phase binding experiments to evaluate the
effect of fibrinogen  peptide on thrombin-GpIb-(1–282)
interaction were performed as detailed above by immobilizing
purified GpIb-(1–282) fragment (10 g/ml) on polystyrene
plates. Purification of platelet GpIb-(1–282) fragment was
performed as detailed previously (20). Thrombin (20 nM to 1.28
Fibrinogen Chain and Thrombin-Platelet Interaction
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M) was incubated in the presence of both 408–427  peptide
and fragment D* at fixed concentrations spanning from 10 to
320 M and from 0.2 and 3.2 M, respectively. The binding
buffer was TBSP. Both the experimental procedure of the bind-
ing assay and the analysis of the experimental data sets were the
same as those used to study the thrombin-fragment D* interac-
tion, detailed above. Control experiments, in which different
concentrations of GpIb(1–282) fragment from 0.31 to 10
g/ml were immobilized on themicroplate wells for binding to
10 nM thrombin, showed that in the time scale of the horserad-
ish peroxidase reactionwith 3,5,3,5-tetramethylbenzidine (15
min), the signal at 450 nm was always linear for all tested GpIb
fragment concentrations. These results validated the assump-
tion that in this solid-phase binding assay the absorbancemeas-
ured at 450 nm after 15 min reflected the amount of thrombin
bound to GpIb. Additional control experiments were also car-
ried out with the synthetic peptide analogGpIb-(268–282), as
a competitive inhibitor of thrombin binding to the immobilized
GpIb-(1–282) fragment. This peptide, encompassing theC-ter-
minal tail 268–282 of GpIb, was synthesized and character-
ized as detailed previously (19). The three sulfated tyrosines,
present in the natural peptide sequence (residue 276, 278, and
279), were replaced by phosphotyrosine.
Effect of HD1 and HD22 Aptamers on Thrombin-Fragment
D* Interaction—The ssDNA-aptamers 5-GGTTGGTGTG-
GTTGG-3 (HD1) and 5-AGTCCGTGGTAGGGCAGGTT-
GGGGTGACT-3 (HD22) were synthesized by Primm s.r.l.
(Milano, Italy). HD1 andHD2 are ssDNA aptamers, which spe-
cifically bind to ABE-I and ABE-II, respectively (21). In these
experiments 500 nM -thrombin was added to fragment D*,
immobilized on microplates as detailed in the previous para-
graph, in the presence of different concentrations of HD22
(20–1280 nM) and HD1 (87.5–5600 nM) and incubated for 60
min. The detection of bound thrombin was performed by an
immunoassay, as described previously.
Hydrolysis of Chromogenic Substrate D-Phe-Pip-Arg-pNA by
Thrombin in the Presence of  Peptide and Fibrinogen Frag-
ment D*—Steady state hydrolysis of the chromogenic substrate
S-2238 was studied in the absence and presence of six different
 peptide concentrations ranging from 2.5 to 320M and frag-
ment D* concentrations spanning from 0.2 to 3.2 M. Throm-
bin was used at 1 nM in 10mMTris-HCl, 0.15 MNaCl, 0.1% PEG
6000, pH 7.50, at 25 °C.
Hydrolysis of PAR1-(38–60) and PAR4(44–66) Peptide
by Thrombin—PAR1-(38–60) (38LDPRSFLLRNPNDKYEPF-
WEDEE60) and PAR4-(44–66) (44PAPRGYPGQVCANDS-
DTLELPDS66) peptides were synthesized by PRIMM (Milan,
Italy). Cleavage of these peptides by 0.1–1 nM thrombin was
monitored by RP-HPLC as detailed previously (22). The
Michaelis-Menten parameters kcat and Km were calculated in
the absence and presence of fixed concentrations of the  pep-
tide ranging from about 2.5 to 320 M. The kcat/Km values of
PAR1 peptide hydrolysis in the presence of fragment D* (from
0.2 to 6.4M)was calculated at a peptide concentration of 1M,
which is a concentration lower than theKm value of the throm-
bin-PAR interaction. Under these conditions, the first order
rate constant of the peptide hydrolysis was proportional to the
kcat/Km value, as experimentally verified. The hydrolysis reac-
tion was performed in 10 mM Tris-HCl, 0.15 M NaCl, 0.1% PEG
6000, pH 7.50, at 25 °C. The kcat/Km values were analyzed as a
function of both  peptide and fibrinogen fragment D* using
the following linkage Equation 2 (23),
kcat/Km	
app kcat/Km
0 kcat/Km
1I/Ki		/Z (Eq. 2)
where Z 1 I/Ki; Ki is the equilibrium dissociation constant
of either  peptide or fragment D* binding to thrombin; I is the
inhibitor concentration; and the superscript 0 and 1 refer to the
kcat/Km value pertaining to free and  peptide- or D*-bound
thrombin form, respectively. Control experiments were also
carried out using 320 M scrambled  peptide to exclude spu-
rious effects generated by ionic strength phenomena.
Binding of [Fluorescein]-Hirudin54–65(PO3H2) to Human
-Thrombin in the Absence and Presence of  Peptide—Fluo-
rescein-conjugated and phosphorylated C-terminal hirudin-
(54–65) peptide, [F]-hirudin54–65(PO3H2), having the se-
quence GDFEEIPEEY(PO3H2)LQ, was synthesized as
described previously (24). Binding of this peptide to ABE-I of
thrombin was studied by monitoring the decrease of the pep-
tide fluorescence occurring upon interaction with thrombin, as
reported previously (25). Fluorescence spectra were recorded
on a Jasco (Tokyo, Japan) spectrofluorometer, as detailed
above. Excitation and emission wavelengths were 492 and 516
nm, respectively, using an excitation/emission slit of 3/5 nm.
During titration experiments, the decrease of fluorescence
intensity at 516 nm was recorded as a function of thrombin
concentration. For all measurements, the long time measure-
ment software (Jasco) was used. Fluorescence intensities were
corrected for dilution (i.e. 8–10%) at the end of the titration.
Data were analyzed by the following binding isotherm Equa-
tion 3 (26), using the program Origin 7.5 (MicroCal Inc.),
F  F0
Fmax  2	 1 Kd LP0
 1 Kd LP0 
2

4	 L
P0
 1 (Eq. 3)
where  is the maximum fluorescence change; Kd is the disso-
ciation constant; L is the total concentration of thrombin; and
P0 is the concentration of [F]-hirudin54–65(PO3H2).
Thrombin-induced Aggregation of Gel-filtered Platelets—
Platelets from healthy volunteers were gel-filtered on Sepha-
rose 2B columns (GE Healthcare) as reported previously (22).
Born’s aggregation of gel-filtered platelets, performed on a
4-channel PACKS-4 aggregometer (Helena Laboratories, Sun-
derland, UK) as detailed previously (22), was induced by 1 nM
thrombin in the absence or presence of different concentra-
tions of  peptide and fibrinogen fragment D*. Control exper-
iments were performed with both 50 M PAR1- and 1 mM
PAR4-activating peptides (PAR1-AP (SFLLRN-NH2) and
PAR4-AP (AYPGKF-NH2), respectively, from PRIMM), 10 M
ADP, and 10 g/ml collagen from Helena Laboratories. The
specific effect of fragment D* was also evaluated by using frag-
ment D at the same concentrations.
Fibrinogen Chain and Thrombin-Platelet Interaction
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Monitoring of Full-length PAR1 Hydrolysis by Thrombin on
Intact Platelets by Flow Cytometry—Gel-filtered platelets from
healthy controls weremixed with 1 nM thrombin at 25 °C in the
absence and presence of the  peptide ranging from 27 to 310
M and of fibrinogen fragment D* from 0.1 to 32 M. After
120 s, the hydrolysis of PAR1 molecules on platelet membrane
was stopped with 1 M D-Phe-Pro-Arg-chloromethyl ketone,
and the uncleaved PAR1 molecules were detected by flow
cytometry, as described previously (22). Briefly, after cleavage
reaction was stopped, platelets were labeled for 30 min at 4 °C
with saturating amounts of phycoerythrin-conjugated anti-
thrombin receptor monoclonal antibodies (SPAN-12 clone;
Beckman Coulter, Milan, Italy), as detailed elsewhere (22). Iso-
type-matched, phycoerythrin-conjugated irrelevant antibodies
were used to measure background fluorescence. Samples were
run through a FACSCanto flow cytometer (BD Biosciences)
with standard equipment. Uncleaved PAR1 expression levels
were reported in terms of mean fluorescence intensity (MFI)
ratio of the SPAN-12 platelet population.
RESULTS
Purification of Fragment D and D*—The purifications of
both fibrinogen fragment D*, containing one A and one 
chain, and of normal fragment D were successfully accom-
plished by DEAE chromatography. Fragment D in SDS-PAGE
showed a molecular mass of about 85 kDa, whereas fragment
D* had a slightly higher molecular mass as compared with
fragment D, in agreement with the presence of the elongated
 chain (Fig. 1A). SDS-PAGE under reducing conditions
and immunoblotting of the reduced sample with an anti-
monoclonal antibody allowed us to identify the genuine
presence of fibrinogen fragment D*, as shown in Fig. 1, B
and C. Purified fragment D* was then used in the functional
and solid-phase binding experi-
ments, where the nominal concen-
tration of the  chain was
assumed the same as that of the
entire fragment D*.
Characterization of the Fibrino-
gen Fragment D* Interaction with
Thrombin—The interaction of pu-
rified fragment D* with thrombin
was studied by a solid-phase binding
assay that showed a specific interac-
tionwith aKd value of 0.4 0.03M
(Fig. 2). The sequence of 20 amino
acids of the  peptide present in the
fragment D* drives this interaction,
as the purified  peptide competi-
tively inhibited with a Ki value of
about 47 M of the thrombin-frag-
ment D* interaction, as shown by
Fig. 2A. This interaction involved
the ABE-II of thrombin, as its bind-
ing was competitively inhibited by
specific ligands of this thrombin
exosite. In fact, the C-terminal
45–57 peptide of hemadin, which
binds to ABE-II (27), was able to competitively inhibit the
thrombin-fragment D* interaction, with a Ki value of 4.2 0.4
M, as shown in Fig. 2B. No significant interactionwas observed
with fragment D (Fig. 2C). The involvement of the ABE-II of
thrombinwas also confirmed by the inhibition of the binding of
500 nM thrombin to immobilized fragment D* by the ssDNA
aptamer HD22 (IC50  81  6 nM; see Fig. 2C), whereas no
effect was observed using the ssDNA aptamer HD1, which
binds to ABE-I of the enzyme (data not shown).
Binding of  Peptide to ThrombinMonitored by Tryptophan
Fluorescence—The binding of  peptide to thrombin causes a
significant increase of tryptophan fluorescence, without appre-
ciable change in themax value.Hence,we exploited this change
for estimating the affinity of the  peptide for thrombin, as
shown in Fig. 3. The corresponding Kd value for  peptide
binding was calculated as 30  5 M, in good agreement with
the value determined by the solid-phase binding experiments
reported above. The increase in the fluorescence quantumyield
suggests that the chemical environment of Trp residues in
thrombin becomes, on average, more rigid and apolar than in
the ligand-free enzyme (28).
Effect of  Peptide and Fibrinogen Fragment D* on Platelet
Aggregation—The fibrinogen  peptide inhibited dose-
dependently the thrombin-induced aggregation of gel-filtered
platelets, up to about 70%, in a specific manner, as demon-
strated by the lack of effect by the scrambled  peptide (see Fig.
4,A andB). Likewise, purified fibrinogen fragment D* inhibited
platelet aggregation up to about 70%, although it was impossi-
ble to reach full inhibition, even at higher fragment concentra-
tions (Fig. 4B). At variance with these findings, no significant
effect was observed with fragment D (Fig. 4B). The analysis of
these data provided IC50 values of 42 3.5M for thepeptide
and 0.47  0.03 M for the D* fragment. Aggregation induced
FIGURE 1. SDS-PAGE of purified fibrinogen fragment D. A, gel was 4–12%polyacrylamide under nonreduc-
ing conditions. Lane 1,purified fibrinogen fragmentD; lane 2, total fibrinogen fraction eluted by 50mM sodium
phosphate, 80 mM Tris, pH 6.80, in the first chromatographic step using DEAE-Sepharose (see text); lane 3,
fraction eluted by 0.5 M NaCl in 20 mM Tris-HCl, pH 8.0, in the second chromatographic step using DEAE-
Sepharose (see text). Themolecularmassmarkers are indicated on the right. B, gel was 4–12%polyacrylamide
under reducing conditions. The sample was fragment D* obtained from the DEAE chromatography. The com-
ponentwith amolecularmassof41,000kDa is theelongated chain fragment contained in fragmentD*. The
otherbandspertain to the chain regionof fragmentD* (37.6 kDa) and the chain fragment (12 kDa). The faint
bandbelow theD*maybe aminor fragment producedbyplasmindigestion, possibly generatedby cleavage
at Ser86 of the  chain (61). The molecular mass markers are indicated on the left. C, Western blot of the
fragment D* sample shown on the left. Detection of the  chain was obtained using the mouse monoclonal
antibody 2.G2.H9, raised against the peptide sequence VRPEHPAETEYDSLYPEDDL of human fibrinogen elon-
gated  chain.
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by saturating concentrations of ADP (10 M), collagen (10
g/ml), PAR1-AP (50M), or PAR4-AP (1mM)was not affected
by the  peptide or fragment D* (data not shown), indicating a
specific interaction with thrombin.
Effects of  Peptide and Fibrinogen Fragment D* on Throm-
bin-GpIb Interaction—Both  peptide and fibrinogen frag-
ment D* inhibited competitively the binding of thrombin to
immobilized GpIb-(1–282) with a Ki of about 40 and 0.5 M,
respectively (Fig. 5, A and B). Instead, no effect was observed
with fragment D (data not shown). The competitive nature of
the observed inhibition by both  peptide and fragmentD*was
confirmed by control experiments performed with the syn-
thetic peptide analogGpIb-(268–282), which binds to throm-
bin with a Ki value of 9 M (19). These findings can explain in
part the inhibitory effect of the  peptide and fragment D* on
thrombin-induced platelet aggregation, because of the activat-
ing role of thrombin-GpIb interaction on platelet aggregation
(22, 29).
Effect of  Peptide and Fibrinogen Fragment D* on Throm-
bin-catalyzed PAR1 and PAR4 Cleavage—Fibrinogen  pep-
tide inhibited the cleavage of the PAR1 substrate, as shown in
Fig. 6A. The inhibitory effect was allosteric in nature, as PAR1-
(38–60) substrate interactswith theABE-I and the active site of
thrombin and not with ABE-II (30), where  peptide binds (9).
Moreover, the inhibitory effect concernedmostly the kcat value,
as shown in Table 1.When the kcat/Km values were analyzed by
a linkage equation (Equation 2) as a function of  peptide con-
centration, a best-fit Ki value of about 40 M was obtained, in
good agreement with the value derived from the GpIb solid-
phase binding and fluorescence titration experiments (Fig. 6B).
No significant effect was observed using 320 M scrambled 
peptide, thus ruling out spurious ionic strength effects. Like-
FIGURE 2. A, binding of thrombin to immobilized fragment D* in the presence of varying concentrations of purified  peptide used at the following concen-
trations (E) 0, (F) 22.5 M, () 45 M, (f) 90 M, and 180 M (
). The solid lineswere drawn according to the best fit parameter values of a simultaneous fit to
single site binding isotherm and a competitive inhibition scheme: Kd of thrombin binding to fragment D* 0.41 0.04M, and Ki of the  peptide 47.5
6 M. B, effect of the 45–57 C-terminal hemadin peptide on thrombin-fragment D* interaction. The solid lineswere drawn according to the best fit parameter
values of a single site binding isotherm and a competitive inhibition scheme: Kd of thrombin binding  0.4  0.03 M, and Ki of the C-terminal hemadin
peptide 4.2 0.4 M. The concentrations of the hemadin peptide were (E) 0, (F) 2 M, () 4 M, (f) 8 M, and 16 M (
). The experimental data set was
analyzedby simultaneous fitting.C, control experiments showing theabsenceof interactionbetween thrombinand immobilized fragmentD.D,bindingof 500
nM thrombin to immobilized fibrinogen fragment D* as a function of the aptamer HD22 concentration. The solid linewas drawn according to the best fit IC50
value equal to 81 6 nM. In the inset, a similar experiment, carried out as a function of the aptamer HD1 concentration, is shown.
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wise, the kcat/Km values of PAR1 hydrolysis as a function of
fragment D* concentration decreased, reaching an asymptotic
value (Fig. 6C). In this case, the value of the equilibrium disso-
ciation constant was about 0.5 M, about 80-fold lower than
that measured for  peptide, in analogy to the results obtained
in solid-phase binding experiments with GpIb. No significant
effect was instead observed using the fragment D (Fig. 6C).
At variance with PAR1, the hydrolysis of PAR4 was not
affected by  peptide, as the kcat/Km valuesmeasured as a func-
tion of the  peptide concentration were scattered around a
mean of about 4  105 M1 s1 (data not shown). In addition,
experiments were carried out using the synthetic peptide sub-
strate D-Phe-Pip-Arg-pNA (S-2238). Both  peptide and frag-
ment D* reduced the catalytic competence of thrombin toward
FIGURE 3. The interaction of  peptidewith thrombinwasmonitored by
adding, under gentle magnetic stirring, to a solution of thrombin (1. 4
ml, 50 nM) in 5mMTris-HCl buffer, pH7.5, containing 0.1%PEG, and 0.15
M NaCl, aliquots (2–5l) of  peptide (2.33 mM). The solid lines represent
the least square fit with Kd value of 30 5 M.
FIGURE 4. Aggregation of gel-filtered platelets by 1 nM thrombin in the
absence (trace 1) and presence of 25 (trace 3), 50 (trace 4), 100 (trace 5),
and 200 M (trace 6) fibrinogen  peptide. A, trace 2 was obtained in the
presenceof 200Mscrambledpeptide,whose sequencewasgeneratedby
the RandSeq program, available the Expasy web site. B, inhibition analysis of
thrombin-induced platelet aggregation in the presence of * peptide (F),
fibrinogen fragment D* (E), and D (). The solid lineswere drawn according
to the best fit IC50 values of 42 3.5M for the  peptide and 0.47 0.03M
for the D* fragment.
FIGURE 5.Bindingof purifiedhuman-thrombin to immobilizedplatelet
GpIb-(1–282) fragment. A, binding of thrombin in the presence of differ-
ent concentrations of  peptide. The solid lineswere drawn according to the
best fit parameter values of a single site binding isotherm: Kd of thrombin
binding 86 7 nM, and Ki of  peptide inhibition 40 6 M. The con-
centrations of  peptide were as follows: (E) 0, (F) 10 M, () 20 M, (f) 40
M, (
) 80 M, (Œ) 160 M, and (ƒ) 320 M. B, binding of thrombin in the
presence of varying concentrations of fragment D* was as follows: (E) 0, (F)
0.2M, () 0.4M, (f) 0.8M, (
) 1.6M, (Œ) 3.2M. The solid linesweredrawn
according to the best fit parameter values of a single site binding isotherm: Kd
of thrombin binding 115 7 nM, and Ki of fragment D* 0.48 0.37 M.
Each point represents the mean of two different measurements. Each exper-
imental data set was analyzed by simultaneous fitting.
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S-2238, with this effect linked mostly to a reduction of the kcat
values, as listed in Table 2.
A dose-dependent inhibition of the hydrolysis of full-length
PAR1molecules on intact platelets was also observed as a func-
tion of increasing concentrations of  peptide, as shown in Fig.
7A. At high peptide concentrations the inhibition reached an
asymptotic value, in agreement with the results obtained with
the synthetic PAR1 peptide. Similar effects were observed with
the fragment D* (Fig. 7B). Thus,  peptide can exert its inhib-
itory effect on platelet activation by inhibiting competitively the
interaction between the enzyme and GpIb and by causing an
allosteric inhibition of PAR1 hydrolysis.
The effect of  peptide on the interaction of thrombin with
[F]-hirudin54–65(PO3H2) was also investigated to assess whether
or not the negative influence of the  peptide on PAR1 but not
PAR4 hydrolysis arose from a conformational change induced in
the ABE-I, where PAR1 but not PAR4 binds. These experiments
showed that theKd value of [F]-hirudin54–65(PO3H2)was not sig-
nificantly changed in the presence of a high concentration of
the  peptide (i.e. 74 M), as shown in Fig. 8. The equilibrium
dissociation constants of the hirudin peptide was in fact equal
to 19.7 1.2 and 14.3 1.5 nM, in the absence and presence of
the  peptide, respectively. Altogether, these findings suggest
FIGURE 6. A, cleavage of 1M PAR1-(38–60) by 0.1 nM thrombin in the absence
(E) andpresence (F) of saturatingconcentrations (320M)of thepeptide. The
concentrations of the cleaved PAR1 peptide over time, [cleaved PAR1]t, were
fitted to the first order equation as follows: [cleaved PAR1]t  1 M  (1 
exp(kt)). Under these pseudo-first order conditions, k e0 (kcat/Km) where e
0 is
the thrombin concentration. The solid lineswere drawn according to the best fit
values of the kcat/Km values equal to 3.83 0.1 10
7
M
1 s1 and 1.76 0.1
107 M1 s1 in the absence and presence of  peptide, respectively. B, values of
kcat/Km of PAR1-(38–60) hydrolysis by thrombin as a function of  peptide. The
solid linewas drawn according to Equation 2 with the best fit values as follows:
(kcat/Km)
0 4 0.1 107 M1 s1, (kcat/Km)
1 1.47 0.1 107 M1 s1, Ki
37.4  6 M. C, values of kcat/Km of PAR1-(38–60) hydrolysis by thrombin as a
functionof fragmentD* (F) and fragmentD () concentration. The solid linewas
drawn according to Equation 2 with the best fit values as follows: (kcat/Km)
0 
3.970.13107M1 s1 (kcat/Km)
11.600.15107M1 s1,Ki0.540.15
M. The vertical bars are the standard deviations from twodeterminations.
TABLE 1
Michaelis-Menten parameters of PAR-1(38–60) hydrolysis by human
-thrombin in the presence of different concentration of  peptide
kcata Km kcat/Km
s1 M 107 M1 s1
 peptide concentration (M)
0 78 2 3.9
2.5 79 2.02 3.9
5 74 1.99 3.71
10 72 2.1 3.43
20 68 2.3 2.96
40 59 2.13 2.77
80 55 2.4 2.29
160 48 2.5 1.92
320 45 2.55 1.76
Scrambled  peptide (M)
320 3.7b
a The standard error percentage was equal to 7% of the parameter value.
b Data were determined at 1 M PAR-1 concentration, following the pseudo-first
order kinetics of its hydrolysis by 0.1 nM thrombin.
TABLE 2
Michaelis-Menten parameters of S-2238 hydrolysis by human
-thrombin in the presence of different concentrations of  peptide
and fibrinogen fragment D*
kcata Km kcat/Km
s1 M 107 M1 s1
 peptide concentration (M)
0 85.0 2.00 4.30
2.5 84.5 2.20 3.84
5 79.6 2.10 3.79
10 79.8 2.30 3.47
20 72.4 2.30 3.18
40 64.7 2.40 2.70
80 63.6 2.80 2.27
160 56.6 2.90 1.95
20 52.2 2.98 1.75
Fibrinogen fragment D* (M)
0.2 74 2.10 3.50
0.4 60 2.06 2.91
0.8 55 1.95 2.82
1.6 50 1.88 2.66
3.2 47 1.94 2.42
a The standard error percentage was equal to 5% of the parameter value.
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that the inhibiting effect of the  peptide on the cleavage of
both PAR1 and the synthetic substrate S-2238 stems mainly
from conformational changes induced in the catalytic site of
thrombin.
DISCUSSION
This study showed for the first time that the fibrinogen
sequence 408–427 in the elongated  chain inhibits the
thrombin-induced aggregation of platelets through a combined
mechanism, impairing both GpIb and PAR1 interactions.
Because it has been shown previously that binding of thrombin
to GpIb could enhance the efficiency of thrombin cleavage of
PAR1 (22), the double effect of  peptide on both GpIb inter-
action and PAR1 cleavage may cooperatively determine a
strong inhibition on platelet activation/aggregation, as indeed
observed. These results are unprecedented, as they show how
the same ligand may hinder at the same time the thrombin
interaction with the two thrombin-elicited receptors involved
in platelet activation, i.e. GpIb and PAR1.
The interaction of fragment D* is energetically driven by the
insertion of the  sequence 408–427, which specifically binds
to ABE-II, as demonstrated by various experimental strategies.
In fact, both  peptide and fragment D* are able to displace
from ABE-II any ligand, which is known to interact with this
site, such as GpIb, the C-terminal hemadin peptide and the
ssDNA aptamer HD22. However, the synthetic  peptide and
the fragment D* showed a different affinity for thrombin. The
Kd value of fragmentD*was about 80-fold lower than that of the
synthetic peptide. These results parallel previous findings on
the binding of fibrinogen  chain to platelet GpIIb-IIIa, where a
70-fold difference in affinity between the synthetic peptide
400–411 of the fibrinogen  chain and the native fibrinogen
fragment D was found (31). Similar results were obtained for
the binding of the N-terminal domain 1–282 of GpIb to
thrombin,where the affinity of the properly sulfatedC-terminal
peptide 268–282 is about 50 times lower than that of the full-
length GpIb-(1–282) fragment (19, 20). These observations
can be reasonably explained by assuming that the protein core
may orient the C-terminal tail of the  chain in a conformation
productive for binding or that the main body of the protein,
beyond the C-terminal extension, enhances affinity by directly
interacting with thrombin. The latter situation is documented
by the crystal structure of the GpIb-thrombin complex (32),
where numerous hydrophobic and electrostatic interactions,
not involving the C-terminal tail, further stabilize the complex.
Although the isolated C-terminal segment of the  chain dis-
plays some nascent secondary structure element, NMR data
indicate that it is highly flexible and intrinsically disordered in
solution (33). This conformational flexibility is also confirmed
by the poor electron density observed for the C-terminal -seg-
ment in the crystallographic structures of fibrinogen D frag-
ment (PDBcodes 1LT9, 1FZC, and 1FIC) (34–36).On the other
hand, the structure of a smaller  chain fragment (PDB code
1FIC) reveals that the segment Leu392–Gly403 extends along the
protein surfacemaking numerous hydrogen bondswith the rest
of the  chain (36). Hence, these contacts may facilitate inter-
FIGURE 7. Effect of  peptide (A) and fibrinogen fragment D* (B) on
thrombin cleavage of PAR1 molecules on gel-filtered platelets. The MFI
ratio was defined as MFI of test histograms/MFI of control histograms (back-
ground fluorescencewithout  peptide). Data are representative ofmean
S.D. recorded in three independent experiments run in duplicate.
FIGURE 8. Plot of the normalized fluorescence fractional change (F 
F0/Fmax) of [F]-hirudin
54–65(PO3H2) (110 nM) as a function of human
-thrombin concentration in the absence (F) or in thepresence (E) of 74
M of  peptide. The solid lines were drawn according to Equation 3, with
best fit parameters Kd 19.7 1.2 nM (F) and 14.3 1.5 nM (E).
Fibrinogen Chain and Thrombin-Platelet Interaction
OCTOBER 31, 2008•VOLUME 283•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 30201
 at N
O
TTIN
G
H
A
M
 TREN
T U
N
IV
ERSITY
 on Septem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
action with thrombin by orienting the elongated -segment in
a conformation productive for binding.
It is known that 10% of circulating fibrinogen molecules
contain the elongated  chain. If we refer to a normal plasma
fibrinogen concentration (200–400 mg/dl corresponding to
6–12 M), this would correspond to a concentration of elon-
gated  chain of about 0.6–1.2 M, nicely overlapping the Kd
value of the fragment D* interaction with the enzyme (Kd 0.5
M). Thus, variations in the ratio between normal and elon-
gated  chain can significantly affect thrombins ligation in
vivo, in keeping with the notion that the maximum change of
the fractional saturation of a macromolecule as a function of its
ligand concentration occurs when the latter is present at levels
similar to the Kd value (37).
Moreover, it has to be outlined that in this study a surrogate
for  fibrin was used. The latter actually interacts with throm-
bin engaging both exosite 2 and 1 (3), although exosite 1 binds
to fibrinogen fragment E with low affinity (3). Thus, we can
speculate that  fibrin can inhibit thrombin-induced platelet
activation more extensively than fragment D*, as it competi-
tively blocks both PAR1 cleavage, via engagement of exosite 1,
and GpIb ligation, via binding to exosite 2, that allosterically
down-regulates also PAR1 cleavage, as demonstrated in this
study.
The allosteric effect linked to binding of the elongated 
chain to thrombin ABE-II resulted in a decrease of the catalytic
specificity of the enzyme for good substrates such as PAR1 and
the synthetic tripeptide S-2238, whereas no significant effect
was observed with the PAR4 peptide-(44–66). Thus, platelet
activation induced by PAR4 hydrolysis, which occurs mainly at
high thrombin concentrations and signals independently from
PAR1 (38), is not affected by either  peptide or fragment D*.
This may also contribute to explain the lack of complete inhi-
bition of the thrombin-induced platelet aggregation observed
even at high  peptide and fragment D* concentrations (see
Fig. 4B). The extracellular region of PAR1 interactswith throm-
bin active site through the sequence 38LDPR41 and with ABE-I
using a hirudin-like sequence (24, 30). This is not the case for
PAR4, which orients Pro44 and Pro46 of the sequence 44PAPR47
in the catalytic pocket but does not interact with ABE-I resi-
dues, using the C-terminal segment (39, 40). Recently, the crys-
tal structure of murine thrombin in complex with the extracel-
lular fragment ofmurine PAR4 confirmed thismode of binding
(41). Perturbation of ABE-I by hirudin or PAR1 exodomain
(residues 42–60) allosterically induces significant structural
changes in the free catalytic pocket of thrombin, mainly at and
around Ser195 (16, 30, 42), that result in altered reactivity of the
enzyme toward synthetic and natural substrates (24–26, 43)
and for binding of inhibitors (44–46). Notably, ligand binding
to ABE-I can either enhance or inhibit the cleavage of small
chromogenic substrates carrying an Arg residue at P1 position,
according to their chemical structure at P2 and P3 positions
(24, 26). Similar conclusions can be drawn for the perturbation
of ABE-II, where binding of some ligands such as prothrombin
fragment F2 orGpIb causes negligible or even opposite effects
on thrombin-mediated cleavage of chromogenic substrates (26,
47). For instance, hydrolysis of S-2238 is inhibited in the pres-
ence of F2, whereas cleavage of tosyl-Gly-Pro-Arg-pNA is
enhanced at a similar extent (26). These findings confirm the
extreme molecular plasticity of thrombin. Unfortunately, crys-
tal structures of thrombin bound to several different ligands,
including the prothrombin F2 fragment (48) (PDB code 2HPQ),
heparin (49) (PDB code 1XMN), and GpIb-(1–282) (32, 50)
(PDB codes 1P8V and 1OOK), indicate that thrombin accom-
modates ABE-II ligands with little, if any, change in its folded
structure and thus do not explain the observed variations in
thrombin function upon ligand binding. These discrepancies
likely arise from crystal packing effects (49) or from the pres-
ence of the D-Phe-Pro-Arg-chloromethyl ketone inhibitor (32,
48), which locks the active site and the specificity exosites of the
enzyme into a fixed conformation, thus abrogating the struc-
tural changes thatmay be induced by ligand binding in solution.
Very recently, the crystal structure of thrombin complex with
the fibrinogen  peptide-(408–427) has been solved at 2.4 Å
resolution. No significant change in the structure of the
enzyme-peptide complex could be detected when compared
with that of free thrombin (9) (PDB code 2HWL). Conversely,
solution studies involving hydrogen-deuterium exchange cou-
pled with matrix-assisted laser desorption ionization time-of-
flight mass spectrometry showed that the gamma peptide
interacts at or near the thrombin ABE-II residues Arg93, Arg97,
Arg173, and Arg175. Moreover, the binding of the  peptide
induces a conformational perturbation to the enzyme as a
whole, by significantly protecting from deuterium exchange
other regions of thrombin, such as the autolysis loop, the edge
of the active site region, some portion of ABE-I, and theA chain
(51). Most of Trp residues in thrombin (i.e. Trp96, Trp141,
Trp148, Trp207, and Trp215) are embedded in segments whose
hydrogen-deuterium exchange efficiency is reduced upon 
peptide binding, whereas other tryptophans (i.e. Trp29 and
Trp237) are in direct contact with the perturbed segments (51).
Hence, it is not surprising that the formation of  peptide-
thrombin complex results in a higher fluorescence intensity of
the enzyme, as shown in Fig. 3, compatible with a conforma-
tional change of thrombin in which the chemical environment
of Trp residues becomes more rigid and hydrophobic (28).
Thus, it is conceivable that the structural perturbations caused
by  peptide binding propagates from the ABE-II residues
toward the S2-S4 subsites of the catalytic cleft of the enzyme
and that these changes are sensed differently by the various P3
residues present in S-2238, PAR1, andPAR4. In agreementwith
this allosteric hypothesis, the kcat/Km value of S-2288 (D-Ile-
Pro-Arg-pNA) by thrombin was increased by 40% at high con-
centration of the synthetic  peptide (160M, data not shown),
demonstrating that even subtle changes in the side chain vol-
ume (Ile 124 Å3; Phe 135 Å3) and electronic properties at
the P3 site can significantly change the allosteric linkage
between binding to ABE-II and hydrolytic activity of thrombin.
In principle, the inhibition of PAR1 cleavage by thrombin
might alsoarise fromconformational transitions inABE-I induced
long range by  peptide binding to ABE-II, leading to a lower
affinityof theC-terminalPAR1segment forABE-I.Theeffectof
peptide on PAR4 cleavage would be negligible because this latter
substrate does not bind to ABE-I. This working hypothesis is
worthy of attention in the light of the proposed, but still
debated, allosteric linkage existing between ABE-I and ABE-II
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(25, 26). To test this hypothesis, we investigated the effect of 
on the binding of the fluorescein-conjugated C-terminal
54–65 peptide of hirudin, [F]-hirudin54–65(PO3H2), a well
known ligand for ABE-I (52). The fluorescence experiments
showed that the binding of [F]-hirudin54–65(PO3H2) was not
significantly affected by the peptide, as shownby Fig. 8. Thus,
it is likely that binding of the elongated  chain to thrombin
induces a conformational change mainly occurring at the cata-
lytic site of the enzyme.
The influence of  chain on venous thrombosis has been
largely recognized (6). In particular, a decrease of this chainwas
associated with a net increase of the risk factor for venous
thromboembolism (6). In contrast, as anticipated above, the
role of this fibrinogen chain for arterial thrombosis is still
debated (6, 7, 13). Clinical studies were conducted in the
attempt to demonstrate whether altered levels of  chain are
inversely or directly correlated with increased risk for arterial
thrombosis. These studies showed that the association of 
chain expression with arterial thrombotic diseases is paradoxi-
cally different from that shown in venous thrombosis. In par-
ticular, the reduced /A ratio occurring in certain fibrinogen
polymorphisms, such as FGG-H2, was not associated with
either acute myocardial infarction (53) or ischemic stroke.
Instead, increased  levels were shown to be positively associ-
ated with an increased risk for both acute myocardial infection
and ischemic stroke (54, 55). However, this association was
shown to be strengthened by the presence of increased levels of
plasma fibrinogen concentration (54, 55) and by FGG 9340T
and FGA 2224G polymorphisms (54, 55). Other factors, such as
total fibrinogenemia (56), the ability of the  chain to protect
thrombin by the heparin-antithrombin inhibition (3), and to
confer to fibrin clots resistance to fibrinolytic degradation, may
represent confounding factors in these studies. Thus, whether
or not the thrombin interaction with the  chain of fibrinogen
plays any pathophysiological role in particular clinical settings
remains controversial. In a recent study on ischemic stroke
(55), both  chain and total fibrinogen levels were elevated in
the acute phase of the disease and subsequently decreased in
the convalescent phase. The increased  chain in the acute
phase stems from the elevation of interleukin-6, which can pro-
mote the synthesis of the A and  chains (57, 58). Thus, fur-
ther studies aimed at investigating the /A ratio rather than
the absolute content of  are needed, especially in clinical sit-
uations like acute thrombosis, where plasma fibrinogen is usu-
ally increased, and thus investigating the absolute  content
alone might be misleading.
Based onour data, indicating a net platelet inhibitory effect of
fibrinogen  chain upon thrombin stimulation, we can infer
that elevation of  chain level, as a possible result of acute
phase response, might exert a beneficial effect on the acute
phase of thrombotic syndromes. A recent study in a baboon
thrombosis model showed indeed that the 410–427  peptide
is able not only to inhibit fibrin-rich thrombus formation,
because of the inhibition of the intrinsic coagulation pathway
(related to inhibition of FVIII activation by thrombin), but also
platelet-rich thrombus formation in the arterial circulation
(59). These findings may be also relevant for clinical applica-
tions of ssDNA aptamers, like HD22, whose specific target is
ABE-II of thrombin (60). On the contrary, the anti-thrombin
and anti-platelet effect of the  chain may be deleterious in
hemorrhagic sequelae of vascular accidents, such as hemor-
rhagic stroke. In the latter condition, the expansion of the vol-
ume of the hematoma causes the post-stroke complications
often responsible for the high mortality from the disease. The
findings reported in this study predict that the presence of
enhanced expression of the  chain could exert deleterious
effects on the thrombin-induced platelet activation and thus on
either the arrest or onset of the hemorrhage. In conclusion, the
role of different expressions of the  chain in circulating fibrin-
ogen may variably influence the thrombotic and hemorrhagic
manifestations in different clinical settings or different phases
of a vascular disease.
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